Lol Corundun, that's a matter of record as you point out, certainly not denying it, but I repeat "disorganised rather than dishonorable" was the major impact on the LAMP delays in construction (it was only completed in August literally weeks before the final operating permit was granted) and first 18 months of operation.
My initial comment was: "Major issues @ LAMP were materials handling & process control at SCALE, no one will understand those other than in practice." Disorganisation thru construction and initial commissioning exacerbated those issues but I doubt any complex plant at scale will avoid them.
Ph2 11ktpa was brought on line, incl expansion of the concentrator, on budget $225M, your "billion" incl's cash burn thru lengthy delays, regardless, money spent.
"What Lynas built for a billion$ and what Alkane will build for under will show an astronomical difference in profits IMO."
Only the RE stream is comparable, but in that context that statement is farcical, marked to current market ALK RE gross revenues are
LAMP NdPr production already annualised 5200tpa, likely +6ktpa 2017, best case ALK 580t 2020. LAMP Dy 50tpa/Tb 20tpa in SEG/HRE concentrate, best case ALK Dy 60tpa/Tb 7tpa 2020. Should be noted China put 1270t Dy & 355t Tb into stockpile last 8 months due to lack of demand/oversupply, HRE have most certainly lost their semi precious metal status.
DZP RE is a byproduct, viability rests with the other product streams IMO, and again, would be great to see ALK successful, in no way will it ever be a rival to Lynas.
- Forums
- ASX - By Stock
- Ann: Significant Drill Intercepts at Depth at TGO
Lol Corundun, that's a matter of record as you point out,...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALK (ASX) to my watchlist
(20min delay)
|
|||||
Last
46.0¢ |
Change
0.020(4.55%) |
Mkt cap ! $278.1M |
Open | High | Low | Value | Volume |
43.5¢ | 46.0¢ | 43.5¢ | $323.3K | 723.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 7565 | 45.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
46.0¢ | 30257 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 7565 | 0.450 |
1 | 19796 | 0.445 |
2 | 9456 | 0.440 |
5 | 19653 | 0.435 |
3 | 27625 | 0.430 |
Price($) | Vol. | No. |
---|---|---|
0.460 | 30257 | 2 |
0.465 | 55283 | 5 |
0.470 | 15000 | 2 |
0.475 | 39550 | 3 |
0.480 | 75030 | 3 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
LU7
The Breakdown: Lithium Universe talks refinery design and lithium processing in strong preliminary feasibility study for Bécancour
RCE
Phase II clinical trial recruitment for R327G topical gel passes halfway, showing promising results against bacterial skin infections
ALK (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online